Despite reports of amifostine possibly protecting nephrotoxicity from cisplatin, it has not been recommended by any guidelines committees or routinely prescribed in clinical practice over the past decade. In this article, we review literature and guidelines regarding use of amifostine in oncology practice for protection against adverse effects from certain chemotherapeutic agents, in particular as a nephro-protectant in patients receiving cisplatin.
No takes yet. Share an insight, caveat, or question.
Ha et al. (2021) studied this question.
Synapse has enriched 4 related papers. Consider them for comparative context: